Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Claudin-8 is an integral membrane protein and a member of the claudin family, which are essential components of tight junctions that form selective permeability barriers in epithelial and endothelial tissues.[1][5][6] These proteins are characterized by four transmembrane domains and are involved in the fine-tuned regulation of paracellular transport and maintenance of cellular polarity and structural integrity.[2][3][4] Claudin-8 in particular helps form a cation-selective barrier in the distal renal tubule and prevents back-leakage of sodium in the distal colon.[1] Altered expression of CLDN8 has been documented in cancers such as colorectal carcinoma and certain renal cell tumors, and it may serve, often with claudin-7, as an immunohistochemical biomarker to differentiate chromophobe renal cell carcinoma from renal oncocytoma.[1] Although claudins have been studied as potential biomarkers and sometimes putative tumor targets in research, CLDN8 itself is not currently recognized as a direct therapeutic target or receptor, and no drugs are known to interact specifically with Claudin-8.[1][5][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Claudin-8 (CLDN8).